NCT06578286View on ClinicalTrials.gov

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2030

Conditions
Breast Cancer
Interventions
DRUG

ARX788

ARX788，1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle

All Listed Sponsors
lead

Fudan University

OTHER

NCT06578286 - ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd | Biotech Hunter | Biotech Hunter